Anti-Ro/La antibodies, classically associated with Sjögren’s syndrome and SLE, have been linked to increased risks of melanoma, T-cell lymphoma, non-Hodgkin lymphoma, and breast carcinoma, particularly in older patients with systemic features such as fever, anemia, or cutaneous lupus erythematosus [41,42]. Here, CALR is linked to T-cell non-Hodgkin lymphoma.